N1-methyladenosine (m1A) is a post-transcriptional RNA modification that plays a critical role in regulating various biological functions and processes, particularly in cancer. Recent research has focused on understanding the mechanisms of m1A modification, including its writers, erasers, and readers. Writers, such as TRMT6, TRMT61A, TRMT61B, TRMT10C, and NML, are responsible for methylating RNA, while erasers like FTO and ALKBH1/3 remove the modification. Readers, including YTHDF1, YTHDF2, YTHDF3, and YTHDC1, recognize m1A-modified RNA. These regulators are involved in cancer development, progression, and prognosis. The review discusses various detection methods for m1A, including traditional techniques like 2D-TLC, HPLC, and LC-MS, as well as high-throughput sequencing approaches such as ARM-seq, m1A-ID-seq, MeRIP-seq, m1A-MAP-seq, m1A-IP-seq, m1A-quant-seq, and m1A-seq-TGIRT and m1A-seq-SS. These methods enable precise identification of m1A modification sites and their implications for cancer. The review also highlights the role of m1A in various cancers, including lung adenocarcinoma, bladder cancer, ovarian cancer, breast cancer, colorectal cancer, and pancreatic cancer. It discusses how m1A modification can be used for cancer diagnosis, treatment, and prognosis. The study emphasizes the importance of further research to refine m1A detection methods and explore the interactions between m1A and other RNA modifications, such as m6A, to better understand their roles in cancer.N1-methyladenosine (m1A) is a post-transcriptional RNA modification that plays a critical role in regulating various biological functions and processes, particularly in cancer. Recent research has focused on understanding the mechanisms of m1A modification, including its writers, erasers, and readers. Writers, such as TRMT6, TRMT61A, TRMT61B, TRMT10C, and NML, are responsible for methylating RNA, while erasers like FTO and ALKBH1/3 remove the modification. Readers, including YTHDF1, YTHDF2, YTHDF3, and YTHDC1, recognize m1A-modified RNA. These regulators are involved in cancer development, progression, and prognosis. The review discusses various detection methods for m1A, including traditional techniques like 2D-TLC, HPLC, and LC-MS, as well as high-throughput sequencing approaches such as ARM-seq, m1A-ID-seq, MeRIP-seq, m1A-MAP-seq, m1A-IP-seq, m1A-quant-seq, and m1A-seq-TGIRT and m1A-seq-SS. These methods enable precise identification of m1A modification sites and their implications for cancer. The review also highlights the role of m1A in various cancers, including lung adenocarcinoma, bladder cancer, ovarian cancer, breast cancer, colorectal cancer, and pancreatic cancer. It discusses how m1A modification can be used for cancer diagnosis, treatment, and prognosis. The study emphasizes the importance of further research to refine m1A detection methods and explore the interactions between m1A and other RNA modifications, such as m6A, to better understand their roles in cancer.